Financial Data and Key Metrics Changes - Net income for 2025 increased by 38.2% year-over-year to $6.3 million, with net cash inflow from operations reaching $3.2 million [5][29] - Total revenue for 2025 was $81.4 million, a decrease from $91.6 million in 2024, while revenue from services increased by 1.8% year-over-year to $60 million [27][28] - Gross margin improved to 52.4% in 2025 from 48.4% in 2024, with service gross margin at 58% compared to 56.8% in 2024 [28][29] Business Line Data and Key Metrics Changes - GlocalMe Life business saw average daily active users (DAUs) increase by 409.1% year-over-year, while average daily active terminals (DATs) surged by 897.9% [8][19] - GlocalMe IoT and GlocalMe SIM also reported significant growth, with average MATs increasing by 127.5% and 133.8% respectively [18][26] - The GlocalMe SIM business line's average daily active terminals increased by 180.8% year-over-year, indicating strong market traction [12] Market Data and Key Metrics Changes - In Q4 2025, Japan contributed 43.6% to total revenue, while Mainland China contributed 26.8%, North America 11.2%, and other regions 18.4% [22] - The average daily data usage per terminal was 1.59 GB in December 2025, reflecting user engagement trends [17] Company Strategy and Development Direction - The company is focused on overcoming the digital divide through innovative connectivity solutions and has invested in three new business lines: GlocalMe IoT, GlocalMe SIM, and GlocalMe Life [6][14] - The introduction of the PetPogo ecosystem aims to bridge the emotional digital divide between pets and their owners, showcasing a strategic shift towards AI and big data connectivity [10][41] Management's Comments on Operating Environment and Future Outlook - Management acknowledged significant macroeconomic challenges in 2025 but emphasized the resilience of their core strategy and the potential for growth in 2026 [5][14] - For Q1 2026, the company expects total revenue to be between $15 million and $17 million, representing a decrease of 9.1% to 14.4% compared to Q1 2025 [14][15] Other Important Information - The company had 206 patents as of December 31, 2025, with 181 approved and 25 pending [21] - Total operating expenses, excluding share-based compensation, were reduced to $9.4 million in Q4 2025 from $13.9 million in Q4 2024 [23] Q&A Session Summary Question: What product lines or geographic areas are expected to drive growth in 2026? - Management indicated that the main growth drivers will be GlocalMe IoT, GlocalMe SIM, GlocalMe Life, and the newly separated PetPogo business line [34][36] Question: Can you provide more information about GlocalMe IoT's growth? - The IoT business is expected to see growth in sectors such as security cameras and in-car infotainment, with significant partnerships established [37][38] Question: Can you elaborate on the PetPogo ecosystem and its expected impact on sales? - The PetPogo ecosystem aims to enhance communication and safety between pets and owners, with strong market interest noted during recent exhibitions [41][44] Question: Will the decline in R&D expenses impact product development? - Management stated that R&D efficiency has improved, and investments will continue in new business lines, particularly the platform business [47][49] Question: What are the reasons for the decline in product sales, and will it continue? - The decline in product sales was attributed to external economic factors, but management believes that service revenue will recover as user engagement increases [58][60]

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $22 million, a decrease of approximately 14% from $25.7 million in 2024 [18] - Gross profit increased to $8.4 million or 38.2% of revenue compared to $8.2 million or 32% of revenue in 2024 [20] - Operating loss narrowed by 33% to $19.7 million in 2025 compared to $29.3 million in 2024 [22] - Net loss narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024 [22] - Operating cash usage reduced by 23% to $16.8 million in 2025 compared to $21.7 million in 2024 [23] Business Line Data and Key Metrics Changes - Revenue from ReWalk Personal Exoskeleton was relatively flat at $8.5 million in 2025 compared to $8.9 million in 2024, with units sold increasing by 22% year-over-year [18] - Revenue from MyoCycle FES bike declined by 50% to $600,000, reflecting a strategic focus on core products [19] - Revenue from AlterG products and services was $12.9 million, a decline of 18% from 2024, primarily due to lower international sales [19] Market Data and Key Metrics Changes - ReWalk achieved reimbursement coverage with three largest Medicare Advantage insurers in the U.S., representing over 16 million covered lives [13] - International distribution for ReWalk expanded, with Germany as the primary test market [13] Company Strategy and Development Direction - The company is executing a strategy to build a diversified biomedical innovation company with multiple technology platforms [3] - A strategic transaction with Oramed is expected to strengthen the financial foundation and support growth initiatives [4] - The acquisition of technology from Skelable aims to enhance the upper extremity rehabilitation market [6][9] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about growth in the core med tech business and improvements in operating expenses driving the company toward positive cash flow [16] - The company is focused on expanding reimbursement coverage and building a stronger payer engagement capability [11] Other Important Information - The company will not provide guidance at this time due to significant transformations and pending transactions [15] - The strategic agreement with Oramed is expected to close soon, providing additional capital support [23] Q&A Session Summary Question: How does the Oramed POD technology align with the company's commercial infrastructure? - Management indicated that the integration of Oramed's technology will drive synergies across med tech and biotech, enhancing the company's decentralized approach to commercialization [27] Question: What is the timeline for the upper extremity robotic assistance product? - Management stated that the product could be 510(k) exempt and expects to complete the necessary studies within 18-24 months [31][32] Question: How does the company plan to address competition in the upper extremity market? - Management acknowledged the presence of competitors but emphasized the unique approach and simplicity of their product [36] Question: Can the company quantify the backlog entering 2026? - Management noted that while the pipeline is growing, specific numbers are not available at this time, but there is a focus on the 22% growth in units year-over-year [51]

Financial Data and Key Metrics Changes - Net revenue for Q2 was $8.3 billion, exceeding expectations, with core operating income of $436 million and a core operating margin of 5.3% [5][4] - GAAP diluted earnings per share was $2.08, while core diluted earnings per share for Q2 was $2.69, reflecting results above expectations [5][4] - Adjusted free cash flow for Q2 was $360 million, with a full-year expectation of over $1.3 billion [7][8] Performance by Business Segment - Regulated Industries generated $3 billion in revenue, up 10% year-over-year, with a core operating margin of 4.8% [6][5] - Intelligent Infrastructure revenue was $4 billion, up 52% year-over-year, with a core operating margin of 5.7%, reflecting broad-based growth [6][5] - Connected Living and Digital Commerce revenue was $1.2 billion, down 8% year-over-year, with a core operating margin of 4.9% [6][5] Market Data and Key Metrics Changes - In regulated industries, revenue was driven mainly by automotive and renewables, with automotive showing signs of recovery [4][19] - Intelligent Infrastructure growth was supported by demand in cloud and data center infrastructure, networking, and communications [4][12] - Connected Living and Digital Commerce showed stability, with growth in robotics and automation partially offsetting declines [6][21] Company Strategy and Development Direction - The company is focused on margin expansion, capital efficiency, and sustained cash generation, with a diversified portfolio driving growth [11][22] - The outlook for Intelligent Infrastructure has been raised to approximately $16.5 billion, driven by growth in all end markets [14][22] - The company is committed to returning capital to shareholders through share repurchases and maintaining an investment-grade credit profile [8][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong performance and momentum entering Q3, with expectations for continued growth across segments [11][12] - The company noted that while there are uncertainties in the geopolitical landscape, it remains optimistic about the recovery in automotive and renewables [19][20] - The outlook for fiscal 2026 has been raised to approximately $34 billion in revenue and $12.25 in diluted earnings per share, reflecting strong demand and operational execution [22][26] Other Important Information - The company repurchased $300 million of shares during Q2 under its existing share repurchase authorization [8] - Inventory days were reported at 75, with a net of inventory deposits from customers at 60 days, consistent with targeted ranges [7][6] Q&A Session Summary Question: What are the growth opportunities in Intelligent Infrastructure? - Management indicated that growth was broad-based across cloud, networking, and capital equipment, with significant increases in revenue across these areas [28][29] Question: What factors are influencing operating margins? - Management noted that while margins are currently at 5.7%, there is potential for improvement due to a favorable mix of business and operational efficiencies [34][35] Question: How is the company planning to allocate cash and manage capital expenditures? - The company plans to allocate 80% of free cash flow to share buybacks, with CapEx expected to be in the 1.5%-2% range of revenue [41][42] Question: What is the status of new customer acquisitions in the data center and AI market? - Management confirmed ongoing discussions with a third hyperscaler and positive momentum in expanding facilities to meet demand [46][47] Question: How is the company addressing supply chain constraints? - Management acknowledged supply chain constraints but expressed confidence in their ability to manage these challenges effectively [50][51]

Yuanbao (NasdaqGM:YB) Q4 2025 Earnings call March 18, 2026 08:00 AM ET Company ParticipantsHuirui Wan - CFOJiqi Sun - Legal CounselRui Fang - Chairman and CEOStella Liu - Investor Relations and Strategy Associate DirectorThomas Wang - Executive Director of Global Investment ResearchConference Call ParticipantsAmy Chen - Equity Research AnalystXiaoyue Ding - AnalystXintao Chen - AnalystYingying Xu - AnalystYue Xu - AnalystOperatorLadies and gentlemen, good day, and welcome to Yuanbao Inc.'s fourth quarter an ...

Yuanbao (NasdaqGM:YB) Q4 2025 Earnings call March 18, 2026 08:00 AM ET Company ParticipantsHuirui Wan - CFORui Fang - Chairman and CEOStella Liu - Investor Relations and Strategy Associate DirectorThomas Wang - Executive Director of Global Investment ResearchConference Call ParticipantsAmy Chen - Equity Research AnalystJiqi Sun - AnalystXiaoyue Ding - AnalystXintao Chen - Research AnalystYingying Xu - AnalystYue Xu - Sell-Side Equity Research AnalystOperatorLadies and gentlemen, good day, and welcome to Yua ...

XOMA Corporation (NasdaqGM:XOMA) Q4 2025 Earnings call March 18, 2026 08:00 AM ET Company ParticipantsBrad Sitko - CIODavid Risinger - Senior Managing DirectorElemer Piros - Managing DirectorJeffrey Trigilio - CFOJuliane Snowden - Investor RelationsOwen Hughes - CEOConference Call ParticipantsPhil Nadeau - Biotech AnalystNone - AnalystOperatorGood day, everyone. My name is Kahealani, and I'll be your conference operator today. At this time, I would like to welcome you to the XOMA Royalty 2025 financial resu ...

Macy’s (NYSE:M) Q4 2026 Earnings call March 18, 2026 08:00 AM ET Company ParticipantsBlake Anderson - VP of Equity ResearchDana Telsey - CEO and Chief Research OfficerJay Sole - Managing DirectorMarni Shapiro - Co-Founder and Managing Partner of Consumer and Retail IndustryPamela Quintiliano - VP of Investor RelationsTom Edwards - COO and CFOTony Spring - Chairman and CEOConference Call ParticipantsBrooke Roach - Managing Director and Senior Equity Research AnalystMatthew Boss - Managing Director and Senior ...

H World Group (NasdaqGS:HTHT) Q4 2025 Earnings call March 18, 2026 08:00 AM ET Company ParticipantsArthur Yu - Incoming CFODan Chee - VP of Equity ResearchHui Chen - CFOHui Jin - CEOIvy Huili Luo - Associate Director of Investor RelationsJihong He - Chief Strategy OfficerLydia Ling - Director of Equity ResearchRonald Leung - VPSijie Li - Credit Research AssociateSimon Cheung - Managing DirectorConference Call ParticipantsXin Chen - Research AnalystOperatorGood day, and thank you for standing by. Welcome to ...

Kanzhun (NasdaqGS:BZ) Q4 2025 Earnings call March 18, 2026 08:00 AM ET Company ParticipantsEddy Wang - Executive DirectorJonathan Peng Zhao - Founder, Chairman, and CEOLaura Chan - Senior Manager of Investor RelationsWenbei Wang - Deputy CFONone - Translator 1None - Translator 2None - Translator 3None - Translator 4Conference Call ParticipantsTimothy Zhao - Equity Research AnalystWei Xiong - AnalystOperatorLadies and gentlemen, thank you for standing by, and welcome to Kanzhun Limited fourth quarter and fis ...

H World Group (NasdaqGS:HTHT) Q4 2025 Earnings call March 18, 2026 08:00 AM ET Company ParticipantsArthur Yu - Incoming CFODan Chee - VP of Equity ResearchHui Chen - CFOHui Jin - CEOIvy Huili Luo - Associate Director of Investor RelationsJihong He - Chief Strategy OfficerLydia Ling - Director of Equity ResearchRonald Leung - VPSijie Li - Credit Research AssociateSimon Cheung - Managing DirectorConference Call ParticipantsXin Chen - Research AnalystOperatorGood day, and thank you for standing by. Welcome to ...